S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:LIVN

LivaNova - LIVN Stock Forecast, Price & News

$63.17
+2.25 (+3.69%)
(As of 08/10/2022 04:35 PM ET)
Add
Compare
Today's Range
$61.53
$63.17
50-Day Range
$57.25
$70.05
52-Week Range
$56.13
$93.89
Volume
309,509 shs
Average Volume
346,663 shs
Market Capitalization
$3.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$98.50

LivaNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.0% Upside
$98.50 Price Target
Short Interest
Healthy
3.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of LivaNova in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.00%
From $2.40 to $3.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

503rd out of 1,108 stocks

Electromedical Equipment Industry

12th out of 23 stocks

LIVN stock logo

About LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LivaNova Stock Up 2.4 %

NASDAQ:LIVN traded up $1.45 during trading on Wednesday, hitting $62.37. The stock had a trading volume of 2,700 shares, compared to its average volume of 346,909. LivaNova has a 12 month low of $56.13 and a 12 month high of $93.89. The company has a market capitalization of $3.33 billion, a PE ratio of -110.66 and a beta of 0.89. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.47 and a current ratio of 2.93. The company's 50-day moving average price is $62.87 and its two-hundred day moving average price is $70.84.

LivaNova (NASDAQ:LIVN - Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.51 by $0.02. LivaNova had a positive return on equity of 9.35% and a negative net margin of 2.74%. The company had revenue of $254.20 million for the quarter, compared to analysts' expectations of $249.55 million. During the same quarter in the prior year, the business posted $0.52 EPS. The business's revenue was down 3.9% compared to the same quarter last year. As a group, sell-side analysts forecast that LivaNova will post 2.4 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Needham & Company LLC decreased their target price on LivaNova from $106.00 to $88.00 and set a "buy" rating for the company in a research report on Thursday, August 4th. StockNews.com upgraded LivaNova from a "hold" rating to a "buy" rating in a research report on Wednesday, August 3rd. Finally, Piper Sandler decreased their price objective on LivaNova from $104.00 to $99.00 in a research report on Thursday, May 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $98.50.

Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Stock News Headlines

LivaNova (NASDAQ:LIVN) Rating Increased to Buy at StockNews.com
Recap: LivaNova Q2 Earnings - Benzinga
Analysts Set LivaNova PLC (NASDAQ:LIVN) PT at $101.50
LivaNova (NASDAQ:LIVN) Cut to "Hold" at StockNews.com
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Company Calendar

Last Earnings
8/03/2022
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIVN
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$98.50
High Stock Price Forecast
$108.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+55.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-135,820,000.00
Pretax Margin
-1.90%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$3.67 per share
Book Value
$24.32 per share

Miscellaneous

Free Float
53,238,000
Market Cap
$3.38 billion
Optionable
Optionable
Beta
0.89

Key Executives

  • Mr. Damien McDonald (Age 57)
    CEO & Director
    Comp: $3.48M
  • Mr. Alex Shvartsburg (Age 51)
    Chief Financial Officer
    Comp: $888.04k
  • Ms. Keyna Pidcock Skeffington (Age 59)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $1.19M
  • Ms. Trui Hebbelinck (Age 50)
    Chief HR Officer
    Comp: $945.32k
  • Mr. Marco Dolci (Age 60)
    Pres of Cardiopulmonary Bus. Unit
    Comp: $1.29M
  • Lindsey Little
    Sr. Director of Investor Relations
  • Deanna Wilke
    VP of Corp. Communications
  • Mr. Matthew Joseph Dodds III
    Sr. VP of Corp. Devel.
  • Dr. Bryan D. Olin Ph.D. (Age 55)
    Sr. VP & Head of Product Devel. - Neuromodulation
  • Mr. Paul R. Buckman (Age 66)
    Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement













LIVN Stock - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LIVN shares.
View LIVN analyst ratings
or view top-rated stocks.

What is LivaNova's stock price forecast for 2022?

6 brokers have issued 12-month price objectives for LivaNova's stock. Their LIVN share price forecasts range from $88.00 to $108.00. On average, they anticipate the company's stock price to reach $98.50 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price.
View analysts price targets for LIVN
or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2022?

LivaNova's stock was trading at $87.43 on January 1st, 2022. Since then, LIVN stock has decreased by 29.0% and is now trading at $62.07.
View the best growth stocks for 2022 here
.

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our LIVN earnings forecast
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its earnings results on Wednesday, August, 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.02. The business earned $254.20 million during the quarter, compared to analyst estimates of $249.55 million. LivaNova had a positive trailing twelve-month return on equity of 9.35% and a negative net margin of 2.74%. The company's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.52 EPS.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $2.25-$2.45 for the period, compared to the consensus estimate of $2.58. The company issued revenue guidance of $1.08 billion-$1.10 billion, compared to the consensus revenue estimate of $1.03 billion.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different retail and institutional investors. Top institutional shareholders include Paradice Investment Management LLC (1.64%), Sumitomo Mitsui Trust Holdings Inc. (1.57%), Allspring Global Investments Holdings LLC (1.48%), Loomis Sayles & Co. L P (1.13%), Victory Capital Management Inc. (0.83%) and Russell Investments Group Ltd. (0.68%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, Marco Dolci and Thad Allen Huston.
View institutional ownership trends
.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $62.07.

How much money does LivaNova make?

LivaNova (NASDAQ:LIVN) has a market capitalization of $3.32 billion and generates $1.04 billion in revenue each year. The company earns $-135,820,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does LivaNova have?

The company employs 3,000 workers across the globe.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.

This page (NASDAQ:LIVN) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.